Identifying Concerns in Arizona with the Inclusion of the Indication or Reason for Use on the Prescription through Focus Groups

Persistent Link:
http://hdl.handle.net/10150/614017
Title:
Identifying Concerns in Arizona with the Inclusion of the Indication or Reason for Use on the Prescription through Focus Groups
Author:
Skulkan, Kaitlyn; Warholak, Terri; Rupp, Michael T.
Affiliation:
College of Pharmacy, The University of Arizona
Issue Date:
2016
Rights:
Copyright © is held by the author.
Collection Information:
This item is part of the Pharmacy Student Research Projects collection, made available by the College of Pharmacy and the University Libraries at the University of Arizona. For more information about items in this collection, please contact Jennifer Martin, Associate Librarian and Clinical Instructor, Pharmacy Practice and Science, jenmartin@email.arizona.edu.
Publisher:
The University of Arizona.
Abstract:
Objectives: To identify stakeholder concerns regarding a potential requirement that all prescriptions include the reason for use or indication. Methods: This was a mixed methods study that employed focus groups. Participants were invited by the Chief Executive Officer (CEO) of the Arizona Pharmacy Association (AzPA) to attend focus groups via webinar. E-mail invites were sent to AzPA members and members of Arizona healthcare professional associations with prescriptive authority except for prescribers who care for animals. The discussion began with a PowerPoint presentation and then questions were presented to guide discussion. Afterwards, questionnaires were distributed through e-mail. Interval level data were analyzed using means and standard deviations. The commentary of the focus group discussion was summarized in themes. Results: Preliminary findings, from two focus groups with a total of seven participants, reflected the following concerns with the inclusion of the indication on prescriptions: compromise of patient privacy; technology capabilities; prescriber time; prescriber compliance; and prior authorization complications. The proposed benefits were: enhanced communication; better medication counseling; reduced prescribing errors; decreased controlled substance diversion; and increased accuracy of a prospective drug use review by pharmacists for patients with complicated disease states. Conclusions: In conclusion, stakeholders were concerned with the implementation of including the indication on prescription orders.
Description:
Class of 2016 Abstract
Keywords:
Arizona; Arizona Pharmacy Association (AzPA); Focus Groups; Indication; Prescription
Advisor:
Warholak, Terri; Rupp, Michael T.

Full metadata record

DC FieldValue Language
dc.contributor.advisorWarholak, Terrien
dc.contributor.advisorRupp, Michael T.en
dc.contributor.authorSkulkan, Kaitlynen
dc.contributor.authorWarholak, Terrien
dc.contributor.authorRupp, Michael T.en
dc.date.accessioned2016-06-21T22:00:44Z-
dc.date.available2016-06-21T22:00:44Z-
dc.date.issued2016-
dc.identifier.urihttp://hdl.handle.net/10150/614017-
dc.descriptionClass of 2016 Abstracten
dc.description.abstractObjectives: To identify stakeholder concerns regarding a potential requirement that all prescriptions include the reason for use or indication. Methods: This was a mixed methods study that employed focus groups. Participants were invited by the Chief Executive Officer (CEO) of the Arizona Pharmacy Association (AzPA) to attend focus groups via webinar. E-mail invites were sent to AzPA members and members of Arizona healthcare professional associations with prescriptive authority except for prescribers who care for animals. The discussion began with a PowerPoint presentation and then questions were presented to guide discussion. Afterwards, questionnaires were distributed through e-mail. Interval level data were analyzed using means and standard deviations. The commentary of the focus group discussion was summarized in themes. Results: Preliminary findings, from two focus groups with a total of seven participants, reflected the following concerns with the inclusion of the indication on prescriptions: compromise of patient privacy; technology capabilities; prescriber time; prescriber compliance; and prior authorization complications. The proposed benefits were: enhanced communication; better medication counseling; reduced prescribing errors; decreased controlled substance diversion; and increased accuracy of a prospective drug use review by pharmacists for patients with complicated disease states. Conclusions: In conclusion, stakeholders were concerned with the implementation of including the indication on prescription orders.en
dc.language.isoen_USen
dc.publisherThe University of Arizona.en
dc.rightsCopyright © is held by the author.en
dc.subjectArizonaen
dc.subjectArizona Pharmacy Association (AzPA)en
dc.subjectFocus Groupsen
dc.subjectIndicationen
dc.subjectPrescriptionen
dc.titleIdentifying Concerns in Arizona with the Inclusion of the Indication or Reason for Use on the Prescription through Focus Groupsen_US
dc.typetexten
dc.typeElectronic Reporten
dc.contributor.departmentCollege of Pharmacy, The University of Arizonaen
dc.description.collectioninformationThis item is part of the Pharmacy Student Research Projects collection, made available by the College of Pharmacy and the University Libraries at the University of Arizona. For more information about items in this collection, please contact Jennifer Martin, Associate Librarian and Clinical Instructor, Pharmacy Practice and Science, jenmartin@email.arizona.edu.en
All Items in UA Campus Repository are protected by copyright, with all rights reserved, unless otherwise indicated.